GC Cell

Mergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S

In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Under the lead

With the rapid growth in the global cell and gene therapy (CGT) market, South Korean pharma firms have increasingly been diversifying into the contract manufacturing area for these novel modalities vi

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as othe